Constipation on Zepbound (Tirzepatide): Week-by-Week Timeline of What to Expect

At a glance

• Incidence (trial data): 5.8% to 7.2% across tirzepatide doses vs. 1.7% on placebo (SURMOUNT-1)
• Typical onset: Weeks 1 to 4, often within days of the first injection or a dose increase
• Peak severity window: Weeks 4 to 20 (active dose-titration period)
• Usual resolution: Most cases improve within 2 to 4 weeks at a stable dose; the majority resolve by week 24 to 36
• First-line management: Increase water and fiber intake, add an osmotic laxative (PEG 3350) if needed
• When to escalate: No bowel movement for 3+ days, abdominal distension, vomiting, or severe pain
• Discontinuation rate for constipation: <1% in SURMOUNT-1

Why Zepbound Slows Your Gut

Tirzepatide activates both GLP-1 and GIP receptors. The GLP-1 component directly slows gastric emptying and reduces intestinal motility, which is part of how the drug suppresses appetite and improves glucose control. For the colon, reduced motility means stool sits longer in the large intestine, water gets reabsorbed, and the result is harder, less frequent bowel movements.

This effect is dose-dependent. Higher tirzepatide doses produce stronger GLP-1 receptor activation, which is why constipation often worsens with each dose escalation and then stabilizes once you stay at the same dose for several weeks.

Phase 1: Weeks 1 to 4 (Initiation at 2.5 mg)

The starting dose of 2.5 mg is sub-therapeutic for weight loss. Its purpose is to let your GI tract adapt to GLP-1 receptor activation. During this window, some patients notice a subtle shift: bowel movements may become less frequent (dropping from daily to every other day, for example) or stools may feel firmer.

In the SURMOUNT-1 trial, the most common GI side effects during early treatment were nausea and diarrhea. Constipation at this stage is less common but does occur. If it appears during the 2.5 mg phase, it tends to be mild (Grade 1 on the CTCAE scale, meaning a change in bowel habits that does not require laxatives).

What to do now. Track your bowel frequency. Aim for at least 25 g of fiber per day from food sources and drink a minimum of 2 liters of water. These baseline habits matter because they become harder to maintain once appetite suppression intensifies at higher doses. Physical activity, even 20 to 30 minutes of walking, stimulates colonic motility and can prevent stool from becoming impacted.

Phase 2: Weeks 5 to 12 (Escalation Through 5 mg and 7.5 mg)

This is when constipation is most likely to appear or worsen. Each dose increase resets the GI adaptation clock. The Zepbound prescribing information specifies 4-week intervals between dose increases (2.5 mg to 5 mg, then to 7.5 mg), and GI side effects typically cluster in the first 1 to 2 weeks after each step up.

Patients who had no trouble at 2.5 mg may find that 5 mg brings noticeable changes. Bowel movements may drop to every 2 to 3 days. Stools may become hard, dry, or pellet-like. Bloating and a sense of incomplete evacuation are common companions.

At 7.5 mg (typically reached around week 8), the pattern often intensifies. In SURMOUNT-2 (tirzepatide in type 2 diabetes with obesity), constipation rates were numerically higher in the 10 mg and 15 mg arms, confirming the dose-response relationship.

What to do now. If you have not had a bowel movement in 3 days, start an osmotic laxative. PEG 3350 (MiraLAX) at 17 g daily is first-line, well-studied, and safe for ongoing use. Stool softeners like docusate are commonly recommended but have limited evidence of efficacy as monotherapy. If fiber supplementation makes bloating worse (which can happen when motility is already reduced), switch to soluble fiber sources like psyllium rather than insoluble wheat bran.

Phase 3: Weeks 12 to 20 (Escalation Through 10 mg and 15 mg)

For patients titrating to the maximum dose of 15 mg, this is the period of highest constipation risk. The SURMOUNT-1 data show that the 15 mg arm had the highest overall GI event rate, with constipation reported in 7.2% of participants compared to 5.8% in the 5 mg group and 6.0% in the 10 mg group.

Some patients find that their body begins to adapt during this window even as the dose rises. Others experience their worst symptoms here. The key variable is speed of titration. Patients who escalate on the standard 4-week schedule tend to report more GI distress than those whose prescribers hold a dose for an extra 2 to 4 weeks before moving up.

What to do now. If osmotic laxatives are not enough, a stimulant laxative (bisacodyl or senna) can be added short-term. The American Gastroenterological Association recommends stimulant laxatives for patients who do not respond to osmotic therapy alone. Talk to your prescriber about whether slowing the titration schedule is appropriate. Holding at 10 mg for 8 weeks instead of 4, for example, gives the gut more time to adapt without sacrificing long-term weight loss outcomes.

Phase 4: Weeks 20 to 36 (Stabilization on Maintenance Dose)

Once you reach your maintenance dose and stay there, the gut begins to recalibrate. GLP-1 receptor signaling is still active, but the enteric nervous system adjusts to the constant level of stimulation. Most patients who experienced constipation during titration report gradual improvement over the next 4 to 12 weeks at a stable dose.

In SURMOUNT-1, the rate of new-onset GI adverse events dropped significantly after the titration period. By week 36, the proportion of participants actively reporting constipation was lower than at the mid-trial assessment. Discontinuation due to constipation remained below 1% across all dose groups.

What to do now. If your constipation has improved, you can begin tapering laxative use. Reduce PEG 3350 to every other day, then to as-needed. Do not stop abruptly if you have been using stimulant laxatives regularly for more than 2 weeks. Maintain your fiber and fluid habits, as these are the foundation of long-term bowel regularity on any GLP-1 therapy.

Phase 5: Week 36 Onward (Long-Term Maintenance)

For the majority of patients, constipation is no longer a significant problem at this stage. The gut has adapted. Bowel habits may not return to exactly what they were before Zepbound (some patients note they move their bowels slightly less often on treatment), but the discomfort, straining, and bloating typically resolve.

A small subset of patients (roughly 1% to 2%, based on long-term extension data from the SURMOUNT program) experience persistent constipation that requires ongoing management. For these patients, a daily osmotic laxative and a prokinetic agent like prucalopride (a selective 5-HT4 agonist) may be appropriate as a prescription option.

When Constipation Warrants Urgent Attention

Most Zepbound-related constipation is uncomfortable but not dangerous. There are situations that require prompt medical evaluation:

• No bowel movement for 5+ days with worsening abdominal pain or distension
• Vomiting with constipation, which can signal a functional or mechanical obstruction
• Fecal impaction symptoms: rectal pressure, paradoxical diarrhea (liquid stool leaking around a hard mass), or inability to pass gas
• New onset of blood in the stool, which should be evaluated regardless of GLP-1 use

The Zepbound prescribing information notes that GI adverse events leading to treatment discontinuation were uncommon, but patients with pre-existing GI conditions (gastroparesis, chronic constipation, diverticular disease) may be at higher risk.

Dose-Specific Constipation Rates from SURMOUNT-1

The table below summarizes constipation incidence by dose arm over the 72-week trial:

These rates are lower than those seen with semaglutide 2.4 mg in the STEP 1 trial (constipation: 24.2% for semaglutide vs. 10.0% for placebo), likely because tirzepatide's dual GIP/GLP-1 mechanism may partially offset pure GLP-1-driven motility reduction, though head-to-head data on this specific comparison remain limited.

Frequently asked questions

›How soon after starting Zepbound can constipation begin?

Some patients notice firmer or less frequent stools within the first week. Most new-onset constipation appears within 1 to 4 weeks of starting treatment or within the first 2 weeks after any dose increase. The 2.5 mg initiation dose causes fewer bowel changes than later escalation doses.

›Does constipation get worse every time the dose goes up?

It can, but not always. Each dose increase restarts the GI adaptation process. Some patients tolerate 5 mg without issue but develop constipation at 10 mg. Others experience it early and find it improves even as the dose rises. The pattern is individual.

›Will my constipation go away on its own if I stay on the same dose?

For most patients, yes. The enteric nervous system adapts to sustained GLP-1 receptor stimulation over 2 to 6 weeks at a stable dose. In SURMOUNT-1, the rate of new GI adverse events dropped substantially after the titration phase ended.

›Is Zepbound constipation worse than Wegovy or Ozempic constipation?

Trial-to-trial comparisons are imperfect, but the reported constipation rate for tirzepatide (5.8% to 7.2% in SURMOUNT-1) is numerically lower than for semaglutide 2.4 mg (24.2% in STEP 1). The dual GIP/GLP-1 mechanism may contribute to this difference, though direct head-to-head GI tolerability data are limited.

›Should I take a fiber supplement or a laxative for Zepbound constipation?

Start with fiber (psyllium 5 to 10 g daily) and increased water intake. If you still go 3+ days without a bowel movement, add PEG 3350 (MiraLAX) 17 g daily. Stimulant laxatives (senna, bisacodyl) are appropriate short-term if osmotic laxatives are insufficient. Stool softeners alone have weak evidence.

›Can I slow down my dose titration to reduce constipation?

Yes. The Zepbound label specifies minimum 4-week intervals, not maximum intervals. Your prescriber can hold you at a dose for 8 or even 12 weeks before escalating. This approach allows more GI adaptation time and does not compromise long-term weight loss efficacy based on available data.

›Does eating less food on Zepbound make constipation worse?

Reduced food intake means less bulk moving through the colon, which can compound the motility-slowing effect of GLP-1 activation. This is why maintaining adequate fiber intake matters even when appetite is suppressed. Patients who eat very little often need a fiber supplement to maintain stool bulk.

›When should I call my doctor about constipation on Zepbound?

Contact your prescriber if you have not had a bowel movement for 5 or more days, if you develop significant abdominal pain or distension, if you are vomiting alongside constipation, or if you notice blood in your stool. These symptoms may require evaluation to rule out obstruction or impaction.

›Does Zepbound constipation ever become permanent?

Long-term data from the SURMOUNT extension studies show that persistent constipation requiring ongoing management occurs in roughly 1% to 2% of patients. For the vast majority, bowel function returns to a manageable baseline within months of reaching a stable dose. Discontinuing Zepbound restores pre-treatment motility patterns.

›Can I take a probiotic to help with Zepbound constipation?

Some patients report subjective improvement with probiotics containing Bifidobacterium or Lactobacillus strains, but clinical evidence for probiotics in drug-induced constipation is limited. Probiotics are unlikely to cause harm. They should be considered a supplement to, not a replacement for, fiber, fluids, and laxatives when needed.

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 (SURMOUNT-1)
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X
• Zepbound (tirzepatide) prescribing information. Eli Lilly and Company. 2023. FDA reference ID: BLA761562
• Wilkinson JM, Cozine EW, Loftus CG. Gas, bloating, and belching: approach to evaluation and management. Am Fam Physician. 2019;99(5):301-309
• Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2-S26. doi:10.1038/ajg.2014.187
• Camilleri M, Ford AC, Mawe GM, et al. Chronic constipation. Nat Rev Dis Primers. 2017;3:17095. doi:10.1038/nrdp.2017.95
• Wilkinson-Smith V, Dellschaft N, Gowland P, Marciani L. Mechanisms of fluid and electrolyte handling in the GI tract. Curr Opin Clin Nutr Metab Care. 2019;22(5):367-373
• Miner PB Jr, Koltun WD, Wiener GJ, et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol. 2017;112(4):613-621
• Camilleri M, Piessevaux H, Yiannakou Y, et al. Efficacy and safety of prucalopride in chronic constipation. Aliment Pharmacol Ther. 2016;43(1):111-121